• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Chung-Han Lee discusses ongoing pembrolizumab/lenvatinib trial in non-clear cell RCC


First study author Chung-Han Lee, MD, PhD, discusses the ongoing open-label phase 2 KEYNOTE-B61 study of frontline pembrolizumab (Keytruda) plus lenvatinib (Lenvima) in non-clear cell renal cell carcinoma. Lee, a medical oncologist at Memorial Sloan Kettering Cancer Center, shared a poster highlighting this study as part of the trials in progress session at the 2021 ASCO Annual Meeting.

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.